ET-901

N/A

Report date: 2025/03/11 15:28:12

Base Information

Drug NameET-901

Drug Alias NameTRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cellCD19 targeting CAR-T cell therapyATHENA CD19-directed chimeric antigen receptor -T CellATHENA CAR-T cell therapyET-901

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Universal CAR-T +[4]

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsUpdating

Therapy Area/IndicationsLupus Erythematosus, SystemicLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesEdigene Inc

China Registration ClassN/A

Develop Information

Active CompaniesEdigene Inc

Inactive CompaniesN/A

Active IndicationsLupus Erythematosus, SystemicLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A